Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.

Early recognition of symptoms is crucial for treating IPEX syndrome with a stem cell transplant.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Topical IKKα inhibitors may help prevent CCS tumours.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Omalizumab may cause hair loss.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Tofacitinib may help treat hair loss in children with alopecia areata.